Ubichem's Jozsef Repasi explains the importance of chemistry services in drug development.
Quintiles' John Hall tells NGP of the burning issues in the biopharmaceutical industry.
Dai Hayward of CellAura Technologies explains how binding assays have held onto their dominance.
Rita Cortvrindt of EggCentris explains how reproductive functions can speed up the development of new drugs.
Taconic's Dr. Holger Kissel explains the significance of in vivo treatments, and tells NGP how researchers are providing efficient and reliable forms of study.